Capricor Therapeutics (CAPR) released expectation-beating results for the fourth quarter, sending the shares up over 5% in aftermarket trading.

Capricor presented preclinical data at the 2024 American Association of Extracellular Vesicles (AAEV) Annual Meeting. The ...

FDA accepts Capricor's Biologics License Application for priority review, advancing deramiocel for DMD cardiomyopathy.

Capricor (CAPR) delivered earnings and revenue surprises of 48.39% and 248.28%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

(CAPR) on ...

Pre-earnings options volume in Capricor Therapeutics (CAPR) is normal with calls leading puts 9:2. Implied volatility suggests the market is ...

AlphaQuest LLC purchased a new position in Capricor Therapeutics Inc (NASDAQ:CAPR – Free Report) during the fourth quarter, ...

The biotechnology company posted adjusted earnings per share of -$0.16 for Q4, beating analyst estimates by $0.01. Revenue came in at $11.13 million, significantly above the consensus forecast of ...

S&P 500 E-Mini futures are up +0.21%, andMarch Nasdaq 100 E-Mini futures are up +0.22% this morning, pointing to a slightly higher open on Wall Street as investors await the ...

NEW YORK, March 19, 2025 (GLOBE NEWSWIRE) -- SL Green Realty Corp. (NYSE: SLG), Manhattan's largest office landlord, today announced the appointment of Peggy Lamb as an Independent Director to the ...